Цертолизумаб Пэгол (CDP870)
Проводит ЮСБ Биосайенсес ГмбХ
Страница компанииМногоцентровое, открытое исследование для оценки фармакокинетики, безопасности и эффективности Цертолизумаба Пэгол у детей и подростков с полиартикулярным ювенильным идиопатическим артритом средней и высокой степени активности
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/501/2012-11-08/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 2–17 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 67 чел. в стране «Россия».
- Центров в реестре: 3 в 3 городах. Список — ниже на странице.
- Плановая дата окончания (06.2023) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 11
Критерии включения
- Study participant is 2 to 17 years of age (inclusive) at Baseline (Visit 2)
- Study participants must weigh ≥10 kg (22lb) at Baseline (Visit 2)
- Study participants must have had onset of signs and symptoms consistent with a diagnosis of Juvenile Idiopathic Arthritis (JIA) (according to the International League of Associations for Rheumatology Classification of Juvenile Idiopathic Arthritis, 2001) and initiation of JIA treatment for at least 6 months prior to Baseline (Visit 2). Eligible JIA categories include: polyarthritis rheumatoid factor-positive, polyarthritis rheumatoid factor-negative, extended oligoarthritis, juvenile psoriatic arthritis, and enthesitis-related arthritis (ERA)
- Study participants must have active polyarticular-course disease, defined as ≥5 joints with active arthritis at Screening and at Baseline
- Study participants must have had an inadequate response to, or intolerance to, at least 1 disease-modifying antirheumatic drug (DMARD) (nonbiologic or biologic). For example, study participant had prior inadequate response to methotrexate (MTX) (based on the Investigator's clinical judgment)
- If the study participant is using MTX, then the study participant must have been on MTX for a minimum of 3 months at Screening. In addition, the dose must have been stable for at least 1 month before Screening at ≥10 to ≤15 mg/m\^2 per week. If the study participant is not using MTX, then the treatment must have been previously withdrawn for documented reasons of intolerability or inadequate response
- If the study participant is using oral corticosteroid therapy, the dose must have been stable for at least 7 days prior to the Baseline arthritis assessment at a maximum dose of 10 mg or 0.2 mg/kg prednisone (or equivalent) per day, whichever is the smaller dose
Критерии невключения
- Study participant has previously been exposed to more than 2 biologic agents
- Study participant previously failed to respond to treatment with more than one tumor necrosis factor alpha (TNFα) antagonist drug
- Study participant is currently receiving or has received any experimental (biological or nonbiological) therapy (within or outside a clinical study) in the 3 months or 5 half-lives prior to Baseline (Visit 2), whichever is longer
- Study participant had previous treatment with a biological therapy for juvenile idiopathic arthritis (JIA) that resulted in a severe hypersensitivity reaction or an anaphylactic reaction
- Study participant previously participated in this study or has previously been treated with CZP (whether in a study or not)
- Study participant has a history of systemic JIA, with or without systemic features
- Study participant has a secondary, noninflammatory type of rheumatic disease or of joint pains (eg, fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere with evaluation of the effect of study medication
- Study participant has other inflammatory arthritis (eg, systemic lupus erythematosus, inflammatory bowel disease-related)
- Study participant has active uveitis or a history of active uveitis within the preceding 6 months
- Study participant has current, chronic or recurrent clinically significant infections
- Study participant has a current sign or symptom which may indicate infection (eg, fever, cough), a history of chronic or recurrent infections within the same organ system (more than 3 episodes requiring antibiotics/antivirals during the 12 months prior to Screening \[Visit 1\]), had a recent (within the 6 months prior to Screening \[Visit 1\]) serious or life-threatening infection (including herpes zoster), or is at a high risk of infection in the Investigator's opinion (eg, study participants with leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections or permanently bed-ridden or wheelchair bound)
Источник: ClinicalTrials.gov, NCT01550003 · запись обновлена в реестре 25 сентября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (6), вторичных — 4
- Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — Week 16
- Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48 — Week 48
- Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 16 — Week 16
- Number of Participants With Anti-Certolizumab Pegol (Anti-CZP) Antibody Level at Week 48 — Week 48
- Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the Study — From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Permanent Withdrawal of the Investigational Medicinal Product (IMP) During the Study — From Baseline (Week 0) up to the Final Visit (70 days after final dose of CZP) (maximum up to 12 years)
Цель исследования
A Multicenter, Open-label Study to Assess the Pharmacokinetics, Safety and Efficacy of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Polyarticular-course Juvenile Idiopathic Arthritis (JIA).
Области и заболевания
Где проходит
3 центра в 3 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 501 от 08.11.2012 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01550003 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.